In the United States, strong consumer demand for organic and raised-without-antibiotics (RWA) poultry and pork, combined with strict FDA Veterinary Feed Directive guidelines, drives robust consumption of MOS additives. American livestock producers and pet food manufacturers actively incorporate yeast-derived MOS into animal rations to promote digestive health and ensure compliance with food safety protocols. Furthermore, a highly consolidated commercial animal feed industry supports steady domestic market expansion throughout the forecast period.

The Mannan Oligosaccharide Market size is expected to reach US$ 1,934.75 Million by 2034 from US$ 963.3 Million in 2025. The market is estimated to record a CAGR of 8.06% from 2026 to 2034. Mannan oligosaccharide (MOS)—a complex glucomannan derived primarily from the outer cell wall of Saccharomyces cerevisiae yeast—delivers exceptional gastrointestinal health benefits, selective pathogen-binding capabilities, and immune system modulation. These functional prebiotic compounds are heavily utilized across poultry feed, swine nutrition, aquaculture diets, pet foods, and human dietary supplements.

The steady expansion of the global mannan oligosaccharide market is primarily propelled by the global phase-out of antibiotic growth promoters (AGPs) in livestock feed, rising consumer demand for antibiotic-free meat and dairy products, expanding commercial aquaculture production, and increasing pet humanization. As animal nutritionists and livestock producers prioritize natural feed additive solutions that enhance intestinal integrity and feed conversion ratios without inducing microbial resistance, MOS continues to serve as an essential gut health management input.

Download Exclusive Sample Mannan Oligosaccharide Market Study - https://www.theinsightpartners.com/sample/TIPRE00024399

What is driving the market?

The rapid global transition toward antibiotic-free livestock production serves as a primary growth driver for the mannan oligosaccharide market. Regulatory bans and voluntary restrictions on sub-therapeutic antibiotic usage in animal feed have forced livestock farmers to seek natural performance enhancers. MOS effectively binds pathogenic bacteria—such as Salmonella and Escherichia coli—by mimicking intestinal binding sites, preventing pathogen colonization on gut mucosal walls and facilitating their safe flushing from the digestive tract.

Additionally, escalating demand for high-protein diets, expanding aquaculture operations, and premiumization in pet food heavily propel market growth. Modern livestock farming relies on MOS to strengthen gut immunity, optimize nutrient absorption, and decrease mortality rates in young animals during high-stress weaning and brooding periods. Continuous bioprocessing innovations—such as enzymatic yeast hydrolysis, high-yield cell wall extraction techniques, and synergistic formulation with beta-glucans—further improve product efficacy and thermal stability during feed pelleting.

Which segment leads?

By end-use application, Poultry commands a dominant market share due to extensive global consumption of chicken meat and eggs, where MOS is widely used to manage intestinal microflora and improve weight gain. Swine and Aquaculture represent fast-growing segments, favored for reducing post-weaning diarrhea in piglets and boosting disease resistance in farmed fish and shrimp.

By source/grade, Yeast Cell Wall Derived MOS leads in volume share owing to abundant raw material availability from bioethanol and brewing yeast streams, while High-Purity Purified MOS represents a high-growth segment for specialized human dietary supplements and companion animal pharmaceuticals.

Which companies are prominent?

The report profiles industry participants, including AngelYeast Co., Ltd, BioFeed, Chengdu iMOS Biotechnology Co., Ltd, EW Nutrition, Hexon Laboratories Pvt. Ltd., Lallemand Inc., Nutritech International Ltd, Ohly, Orffa, and Titan Biotech, while analyzing competitive strategies and innovation developments.

These prominent market participants focus on securing high-quality yeast biomass sources, optimizing autolysis and extraction efficiencies, and expanding international distribution networks. Strategic differentiation relies on proving consistent pathogen-binding capacities through controlled clinical trials, offering low-dust micro-granulated formulations, and providing tailored technical support to feed mills.

What is changing in 2026?

In 2026, the mannan oligosaccharide market is shifting toward multi-functional prebiotic blends, precision animal nutrition, and circular yeast co-product recovery. Feed formulators are increasingly combining MOS with organic acids, essential oils, and probiotics to create comprehensive gut-health solutions that replace multiple individual feed additives. Furthermore, producers are deploying advanced enzymatic hydrolysis to maximize the release of bio-available mannan fractions and improve solubility in liquid calf milk replacers and aquaculture feeds.

What are the major investment opportunities?

The strongest investment opportunities lie in expanding enzymatic yeast processing infrastructure in major agricultural regions, developing specialized MOS formulations tailored for intensive aquaculture farming, and formulating high-purity prebiotics for human gut microbiota supplements. Additional growth potential exists in establishing regional supply partnerships across fast-expanding livestock producing nations in Asia Pacific and Latin America.

Frequently Asked Questions (FAQ)

1. What is the projected market size and CAGR for the Mannan Oligosaccharide Market? The Mannan Oligosaccharide Market size is expected to reach US$ 1,934.75 Million by 2034 from US$ 963.3 Million in 2025, recording a CAGR of 8.06% from 2026 to 2034.

2. What are the key drivers behind the growth of the Mannan Oligosaccharide Market? The market is primarily driven by global regulatory bans on antibiotic growth promoters, rising consumer demand for antibiotic-free meat, expansion in poultry and aquaculture production, and pet food premiumization.

3. How does mannan oligosaccharide improve animal gut health? MOS acts by selectively binding to mannose-specific lectins on harmful intestinal pathogens like Salmonella and E. coli, preventing them from attaching to the gut wall while stimulating beneficial microflora and immune responses.

4. What is the primary source of commercial mannan oligosaccharide? Commercial MOS is predominantly extracted from the cell walls of Saccharomyces cerevisiae (baker's or brewer's yeast) during controlled enzymatic hydrolysis and purification processes.

Related Reading / Reports

Explore additional Business Market Insights research covering animal feed additives, prebiotics, and bioprocessing ingredients:

• Prebiotic Feed Additives Market — Global market sizing, oligosaccharides, inulin, and livestock nutrition trends.

• Probiotics in Animal Feed Market — Analysis of direct-fed microbials, gut health management, and antibiotic alternatives.

• Yeast Extract Market — Insights into Saccharomyces cerevisiae processing, bio-nutrients, and industrial fermentation inputs.

• Animal Health Ingredients Market — Coverage of feed additives, nutritional supplements, and veterinary healthcare products.

About Us

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients find precise solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Chemicals and Materials, Animal Nutrition, Food and Beverages, Healthcare, and Specialized Industrial Manufacturing.

Contact Us

If you have any queries about this comprehensive market report or would like to request further details, please reach out to our team:

• Contact Person: Sameer Joshi

• E-mail: [email protected]

• Phone: +1-646-491-9876

• Website: www.theinsightpartners.com

• Also Available in :

  KoreanGermanJapaneseFrenchChineseItalianSpanis